Ventyx Biosciences Inc (VTYX) Stock
VTYX is no longer traded. Ventyx Biosciences was acquired by Eli Lilly (LLY) in March 2026.
Each VTYX share was exchanged for $14.00 in cash. Prices on this page are historical; the last trade was March 3, 2026 at $14.00.
See Eli Lilly (LLY) stock →Ventyx Biosciences stock price history
VTYX final trading statistics
- Final close
- $14.00
- Final trading day
- Mar 3, 2026
- Market cap at delisting
- $1.00B
- Shares outstanding
- 71.75M
- Final 52-week range
- $0.78 – $25.00
- Avg. volume (final 3 mo.)
- 3,656,869
- All-time high (split-adj.)
- $46.65 · Mar 2023
- All-time low (split-adj.)
- $0.84 · Apr 2025
- Return since IPO
- -33.4%
- Beta
- 1.27
- Book value / share
- $2.68
- Price / book
- 5.22
Ventyx Biosciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$135.1M | -$1.98 |
| FY2023 | $0.00 | -$193.0M | -$3.30 |
| FY2022 | $0.00 | -$108.4M | -$2.05 |
| FY2021 | $0.00 | -$83.7M | -$4.45 |
| FY2020 | $0.00 | -$28.2M | -$1.04 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.
Ventyx Biosciences stock FAQ
What happened to Ventyx Biosciences stock?
Ventyx Biosciences was acquired by Eli Lilly (LLY) in March 2026. Shareholders received $14.00 in cash for each share. VTYX stock stopped trading on the Nasdaq, with a final close of $14.00 on March 3, 2026.
What did Ventyx Biosciences shareholders receive?
Each VTYX share was converted into $14.00 in cash. The deal was valued at about $1.2 billion.
Is VTYX stock still trading?
No. VTYX was delisted from the Nasdaq in March 2026 and no longer trades on a U.S. exchange.
What was the last price of VTYX stock?
VTYX closed at $14.00 on its final trading day, March 3, 2026, for a market value of about $1.00B.
What were Ventyx Biosciences's revenue and earnings in its last full fiscal year?
Ventyx Biosciences reported revenue of $0.00 and net income of -$135.1M in fiscal 2024, its last full year as a public company.
When did Ventyx Biosciences go public?
Ventyx Biosciences Inc stock began trading on October 21, 2021.